Head to Head Comparison: Ovid Therapeutics (NASDAQ:OVID) versus Liquidia (NASDAQ:LQDA)

Liquidia (NASDAQ:LQDA) and Ovid Therapeutics (NASDAQ:OVID) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Liquidia and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Valuation & Earnings

This table compares Liquidia and Ovid Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32 million	37.56	-$68.92 million	$1.37	48.49
Ovid Therapeutics	$7.25 million	73.00	-$17.41 million	($0.31)	-8.74

Ovid Therapeutics has lower revenue, but higher earnings than Liquidia. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Liquidia and Ovid Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2	3	5	1	2.45
Ovid Therapeutics	1	0	8	1	2.90

Liquidia presently has a consensus price target of $98.08, suggesting a potential upside of 47.65%. Ovid Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 121.40%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Liquidia.

Volatility & Risk

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Institutional & Insider Ownership

64.5% of Liquidia shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Liquidia beats Ovid Therapeutics on 8 of the 14 factors compared between the two stocks.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.